课题基金 / 基金详情

Immune Responses to Malaria and HIV Infection and Immunization - Clinical Core

Immune Responses to Malaria and HIV Infection and Immunization - Clinical Core
对疟疾和艾滋病毒感染的免疫反应和免疫接种 - 临床核心
批准号:
10198679
负责人:
Margaret Juliana McElrath
金额:
$16.28万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-07-19 至 2022-06-30

项目摘要

项目成果

Margaret Juliana McElrath的其他基金

相似基金

相关文献

中文摘要
翻译
弗雷德·哈钦森癌症公司疫苗和传染病部门(VIDD)的临床核心 研究中心(FHCRC)将提供临床医学、人体研究、 疫苗试验和人类免疫学,以支持合作的科学目标,重点是 预防和控制疟疾和艾滋病毒。为了最有效地支持协作的不同目标 对于项目,CC将利用各种资源,包括:1)存档样本(例如,冷冻保存的PBMC, 血清、血浆)来自相关已完成或正在进行的临床试验的研究参与者,这些试验包括 协作项目的主要临床样本来源;2)从现有临床样本中新获得的样本 自然历史和控制队列以及来自专门设计的子研究,以实现更全面的 正在进行或计划中的疫苗或治疗试验中的分析;以及3)通过临床获得的样本 合作的临床医生在专业免疫储存库的安全采样方面的专业知识 (例如,骨髓、淋巴结、粘膜)在人类志愿者中使用微创程序。
英文摘要
The Clinical Core, based within the Vaccine and Infectious Disease Division (VIDD) at Fred Hutchinson Cancer Research Center (FHCRC), will provide relevant expertise in clinical medicine, human subjects research, vaccine trials, and human immunology in support of the scientific aims of the Collaboration focused on the prevention and control of malaria and HIV. In order to most efficiently support the diverse aims of Collaboration projects, the CC will utilize a variety of resources including: 1) archived samples (e.g., cryopreserved PBMC, serum, plasma) from study participants in relevant completed or ongoing clinical trials, which comprise the primary source of clinical samples for Collaboration projects; 2) newly obtained samples from existing clinical natural history and control cohorts and from specifically designed sub-studies to enable more comprehensive analysis within ongoing or planned vaccine or treatment trials; and 3) samples acquired through the clinical expertise of collaborating clinicians accomplished in the safe sampling of specialized immunological reservoirs (e.g., bone marrow; lymph nodes; mucosa) using minimally invasive procedures in human volunteers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CoVPN 3003 A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older LC 3
HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3
HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals: LC
国内基金
海外基金
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data